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Improved and cheaper molecular diagnostics allow the shift from “one size fits all” therapies to 
personalised treatments targeting the individual tumor. However, the wealth of potential targets 
based on comprehensive sequencing remains a yet unsolved challenge that prevents its routine use 
in clinical practice. Thus, we designed a workflow that selects the most promising treatment targets 
based on multi‑omics sequencing and in silico drug prediction. In this study we demonstrate the 
workflow with focus on bladder cancer (BLCA), as there are, to date, no reliable diagnostics available 
to predict the potential benefit of a therapeutic approach. Within the TCGA‑BLCA cohort, our 
workflow identified a panel of 21 genes and 72 drugs that suggested personalized treatment for 95% 
of patients—including five genes not yet reported as prognostic markers for clinical testing in BLCA. 
The automated predictions were complemented by manually curated data, thus allowing for accurate 
sensitivity‑ or resistance‑directed drug response predictions. We discuss potential improvements of 
drug‑gene interaction databases on the basis of pitfalls that were identified during manual curation.
The rapid advance of technologies for the molecular profiling of tumors led to the discovery of novel treatments 
targeting the individual tumor. This allowed a shift from “one size fits all” to a more specific treatment in several 
cancer entities, such as breast, lung and colorectal cancer. However, a standardized method to identify potential 
targets from molecular data is still missing and prevents the implementation in clinical practice. In comparison 
to other cancer entities, in bladder cancer (BLCA) potential treatment targets are still relatively poorly investi-
gated and individualized treatment concepts are far behind other cancer entities. Therefore, we aimed to design 
a workflow for an in silico drug prediction with an in-depth showcase study on muscle-invasive bladder cancer.
More than 3 decades of development in empiric systemic therapies have passed without remarkably changing 
the numbers of deaths caused by bladder  cancer1. Recent advancements include immunotherapies in BLCA, 
which have brought the first significant progress in survival since platinum-based chemotherapy regimens were 
introduced in the mid  1980s2. However, in recent years the 5-year overall survival has only been improved by 
5%—and the long-term effects of immunotherapies are still to be  evaluated3.
BLCA is among the cancer types with the highest total mutational  burden4. This molecular diversity of BLCA 
might be one of the major reasons for the low response rates of BLCA to empiric treatments. Moreover, about 
two thirds of BLCA are exposed to APOBEC mutagenesis, which increases the mutational diversity within each 
individual tumor during development. At the transcriptomic level, BLCA can be divided into molecular subtypes 
and clinical implications of these classifications have already been  suggested5. Nevertheless, transcriptome-based 
classifications alone do not seem to be optimal for selecting the right therapeutic approach, as subtypes are still 
highly heterogeneous and do not adequately reflect the genomic individuality of each BLCA tumor. Improved and 
cheaper genomic sequencing techniques made routine use of molecular diagnostics affordable, which potentially 
allows the shift from “one size fits all” to personalized therapies.
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To facilitate such a genomic marker-driven personalized therapy approach in BLCA, the first step is the iden-
tification of clinically relevant and actionable genomic alterations. Thus, in this study we used the TCGA-BLCA 
cohort as a starting point and aimed to determine potentially actionable genes and associated drugs based on 
the mutational landscape of muscle invasive bladder cancer. Moreover, we integrated transcriptomic data and 
existing evidence from other cancer entities to enrich the genomic-based information. The TCGA cohort based 
predictions and the developed workflow can now be used as a prognostic tool to further shift pretreatment 
diagnostics and decision making from an empiric towards an individualized marker-driven therapy strategy.
Results
Variant calling, quality control and variant filtering. We first performed variant calling from whole-
exome sequencing (WES) data from the TCGA-BLCA  cohort6. The derived single nucleotide variants (SNVs) 
and copy number variations (CNVs) served as a base for a query in “The Drug Gene Interaction Database” 
(DGIdb)7 to identify variants with non-curated* drug gene interaction (DGI) information (* = all DGIs not 
yet curated by manual curation or not derived from an expert curated DGI database will hereafter be called 
“non-curated” to highlight their level of evidence). Intending to target clinically relevant mutations only, we per-
formed a prediction of the variant’s effect on the protein function and included only those variants with poten-
tially damaging effect. Furthermore, only variants with a high impact, e.g. missense or stop-gain variants, were 
retained, thereby removing variants with likely limited effect on the protein. Subsequently, we filtered by the 
cohort prevalence of affected genes and the type of drug-trials the DGIs had been derived from. Finally, selected 
DGIs not present in an expert curated database were manually curated (see Fig. 1 and “Methods” for a detailed 
description) and transcriptome based drug-response scores (DRS) were calculated, if available.
Variant calling compared to previous TCGA analysis. Variant calling from the 412 patients` tumor 
genomes resulted in an unfiltered variant count (UVC) of 201,937 genomic variations. Quality metrics identi-
fied a high overlap with previous variant calling from the TCGA-BLCA cohort e.g. with Robertson et al.6 (see 
supplements). With a median agreement of 98.3%, the identified SNVs in particular were highly similar to the 
previously documented analyses, despite using a more conservative approach than Robertson et al.6. For identi-
fied CNVs the median agreement with previously reported CNVs was 84.6%.
Variant and drug filtering. DGIdb is the largest cumulative database for DGIs. It works as a widely used 
open source tool to collect DGIs by text mining from public resources, such as publications and  databases7, of 
which several are expert-curated. By querying DGIdb, we identified 34,039 SNVs and CNVs with existing refer-
ences for non-curated DGIs (in total 16.9% of UVC).
Before DGIdb-based filtering, tumor samples showed a wide range of mutational load from 1 to 7320 SNVs 
(median 293). The vast majority of samples presented drug-related SNVs after filtering, ranging from 0 to 574, 
with a median of 23 mutations (see Fig. 2a). Variants fulfilling the subsequent filtering steps to only select damag-
ing SNVs with high predicted impact on the protein, still presented a large subset of non-synonymous SNVs (see 
Figure 1.  Workflow design—the diagram depicts the key steps of our in silico drug prediction. (a) After 
variant calling of whole-exome sequencing (WES) data from the TCGA bladder cancer cohort, a query was 
performed on the “Drug Gene Interaction database” (DGIdb) to identify targetable genomic alterations amongst 
the discovered mutations. (b) During the subsequent fully automated filtering phase, further selection criteria 
were applied. (c) In the semi-automated filtering phase manual curation complemented the automated query of 
the expert curated CIViC (“Clinical Interpretation of Variants in Cancer”) database, resulting in the final set of 
genes and drugs. (Microsoft PowerPoint; version 16.44).
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Fig. 2b). The CNV count per sample changed from 0 to 595 (median 52) prior to filtering, to 0 to 243 (median 
44) after (see Fig. 2c). Copy number gains and amplifications outweighed copy number losses and deep deletions 
(see Fig. 2d). Thus, here the applied filters to only select deep deletions or amplifications led to a minor decrease 
in CNVs evaluated for treatment prediction.
Next, we assigned the non-curated DGIs to the individual samples. This resulted in a “drug load” per sample, 
representing all predicted drugs with a gene-dependent recommendation. Figure 3 illustrates the effect of each 
step of filtering on the “drug load”. The combined “drug load” considering all drugs for all SNVs and CNVs 
varied from 0 to 1896 (median 1422) (Fig. 3a). Filtering DGIs for the selected variants with predicted clinical 
relevance (high transcriptome impact score) reduced the “drug load” to 0–1478 (median 274) drugs per sample 
(Fig. 3b). Applying cohort prevalence filters and excluding drugs without relation to cancer therapy resulted 
in 0–191 (median 57) drugs per sample (Fig. 3c). Manual curation and the CIViC (“Clinical Interpretation of 
Variants in Cancer”; https ://civic db.org) query created a final total “drug load” of 0–66 drugs (median 27) per 
sample (Fig. 3d).
From the remaining 11,938 variants present across the cohort (6% of UVC), we demanded a variant cohort 
prevalence of 15%, which resulted in a set of 109 genes and 207 drugs (for details see suppl. Fig. S2). Thus, of the 
initial 4117 DGIs 91% were dismissed during automated filtering before manual curation and CIViC query. A 
majority of drop out resulted from both variant- and drug-related criteria. For instance, drugs not being related 
to cancer therapy caused the dismissal of 18% of DGIs. Low cohort prevalence and non-damaging variants 
resulted in the removal of a further 18% (see Figs. 3, 4a).
Manual curation and CIViC integration. Up to this point in our investigation the workflow was fully 
automated (see Fig. 1a,b). The selected DGIs resulted in a set of 109 genes and 207 associated drugs (see suppl. 
Fig. S1). However, the level of evidence of selected DGIs could be separated into two groups. The first group was 
supported by CIViC DGI references. CIViC is an open source database for expert curated DGI references, which 
we integrated into our workflow to be automatically  queried8. The second group was compiled of non-curated 
DGIdb entries and lacks information on the actual support of the treatment. To base our in silico predictions on 
proven DGIs only, we conducted a manual curation of non-curated DGIs (see “Manual curation of drug–gene 
interaction”). Note that we selected all SNV-dependent non-curated DGIs for manual curation. Manual curation 
is very time consuming and we expected similar methodological results for CNV-dependent DGIs. The non-
curated SNV-dependent DGIs selected for manual curation represent 26% of all selected DGIs (see Fig. 4b). It 
Figure 2.  Filtering shows distinct effects on the SNV/CNV selection. (a) Barplot illustrates the log-scaled 
mutation load per sample for non-synonymous mutations, before (blue bars) and after (red bars) filtering for 
provided drug-gene interactions. Bars are overlying, not stacked. (b) Boxplots depict the distribution of SNV 
types after filtering for drug-related variants. (c) The barplot shows the differences of CNV load per sample 
throughout filtering. The overlying bars represent CNV load before (blue bars) and after (red bars) filtering 
for non-curated drug-gene interactions. (d) Boxplots illustrate the distribution of CNV types across TCGA-
BLCA samples after filtering for drug-related CNVs (DEL deletion, 0 copies; LOSS copy number loss, 1 copy; 
GAIN copy number gain, 3–4 copies; AMP amplification, > 4 copies). (R Core Team (2019). R: A language and 
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Figure 3.  Development of the “drug load” along the filtering process. Each bar depicts a “drug load” per patient. 
Bars are not stacked, but overlying. Note that the y-axes change throughout the filtering. Drugs tested in bladder 
cancer trials or trials generally including solid tumors (ct) were distinguished from drugs used in general cancer 
trials (nct) and from medications not related to cancer in general. Purple bars illustrate the total drug load per 
sample. Drugs with no reference to cancer therapy are illustrated in yellow (other). (a) Barplot illustrates the 
“drug load” for all SNVs and CNVs after querying DGIdb before any filters were applied. In (b) “drug load” 
after filtering for clinically relevant variants is depicted. In (c) cohort prevalence filters for variants were applied 
and drugs with no reference to cancer therapy were excluded. (d) Barplot illustrates the final “drug load” for 
curated drug-gene interactions after integration of CIViC and manual curation results. (R Core Team (2019). R: 
A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 
https ://www.R-proje ct.org/)57.
Figure 4.  Influence of automated and manual filtering on the number of drug-gene interactions (DGIs). (a) 
The pie chart illustrates the fraction of DGIs filtered in an automated fashion, grouped by filter criteria. In (b), 
the fractions of DGIs that underwent curation or CIViC query are shown (note that not all available DGIs were 
manually curated, as this was beyond the scope of this study), whereas in (c), the assessment categories of the 
manually or CIViC curated DGIs are depicted. Note that combination treatments are excluded in this plot, 
since they all refer to the same DGIs and would thus be counted twice. (R Core Team (2019). R: A language and 
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can be expected that the fraction of non-curated DGIs will decrease over time, with more comprehensive infor-
mation available in databases such as CIViC.
Interestingly, manual curation uncovered 62% of all investigated DGI references to be irrelevant, due to 
missing evidence of single agent efficacy or missing references to drug or gene itself. Commonalities of sources 
without proper reference to the DGI of interest include administration of the drug as part of a therapy regimen 
(which does not allow for evaluation of the single agent efficacy) and exclusive citations of either drug or gene 
in the list of references. In respect to all manually curated DGIs, 23% proved to be irrelevant due to exclusion 
in manual curation.
By extracting information concerning the direction of the DGI (sensitivity/resistance) from the DGI refer-
ences, we were able to create binary predictions of response direction. While a majority of 57% of DGIs described 
sensitivity reactions, 12% of DGIs referred to resistance and 8% contained conflicting evidence (see Fig. 4c). 
Additionally, we used information from the mined references to annotate DGIs and discovered 10 reasonable 
combination therapies. Finally, filtering out DGIs neither supported by CIViC information nor by manual cura-
tion, reduced the number to 21 final genes and 72 drug/drug combinations.
To exemplify the results of the manual curation we depict examples for each possible categorie of annotation 
(SENSITIVITY/RESISTANCE/UNKNOWN).
A SENSITIVITY for veliparib is predicted by our algorithm, amongst others, in case of an ATM mutation 
due to the work of Subhash et al.9. In their study on gastric cancer they identified sensitivity for veliparib in case 
of ATM loss-of-function mutations of  ATM9.
Yonesake et al. identified a mechanism of resistance to cetuximab in case of ERBB2 activating  mutations10. 
Their study was called by our algorithm as a non-curated reference, manual curation led to the annotation of 
RESISTANCE in case of  mutation10.
The efficacy of a DGI cannot be evaluated, if, within the referred study, the drug was administered within a 
therapy regime but not as a single acting agent, e.g. for a DGIdb reference for an interaction between PIK3CA 
and  fluorouracil11. An non-curated DGI for FGFR3 and ponatinib was called on the results of the study “Com-
bined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in 
FGFR2 mutant endometrial cancer models” by Gozgit et al.12. The call was a result of the DGIdb query algorithm, 
which found FGFR3 mentioned in the running text of the study but without any reference to an interaction to 
 ponatinib12. In the aforementioned cases DGIs were annotated as UNKNOWN and dropped out from further 
utilization and analysis.
We want to point out that due to the fluid variables of our algorithm (entries in DGIdb, CIViC) in the future 
the dataset is likely to consist of partially different references.
Integration of transcriptomic data. To further consolidate the genomic-level predictions, we used tran-
scriptome-dependent drug response scores (DRS) derived from the NCI-60 cell lines. The DRS were applied on 
each individual sample. DRS were measured for 26% (19/72) of the finally selected drugs (see Fig. 5 and suppl. 
Fig. S2). Note that a positive DRS indicates that cell-line samples responded favorably to the tested drug depend-
ing on their level of gene expression, i.e. a positive DRS is interpreted as sensitivity. However, it is important to 
note that a negative DRS does not implicitly mean that the cell line sample was resistant to the applied drug, but 
rather that no sensitivity could be observed (also see “Integration of DRS”).
Final drug and gene panel. Based on the previously described steps, we identified a set of 21 actionable 
genes and 72 corresponding drugs or drug combinations as promising target-driven therapy suggestions for 
muscle invasive bladder cancer (see Fig. 6; suppl. Figs. S3, S4). In total 95% of TCGA-BLCA samples could be 
covered by our set of selected drugs and genes by being represented with at least one predicted DGI.
The finally selected set represents a mix of genes and drugs known in the context of bladder cancer, together 
with interesting potential new targets. 45 of the identified 72 drugs or drug combinations are currently or for-
merly tested in BLCA clinical trials. While being tested in solid tumor basket trials or other solid tumor entities, 
at the time of our investigation 17 of the listed drugs have not been tested in explicit BLCA trials yet (ceritinib; 
CUDC-907 (fimepinostat); dacomitinib; DS-7423; entrectinib; gedatolisib; idelalisib; letrozole; margetuximab; 
MK-2206; PD-0325901 (mirdametinib); PF-04691502; pictilisib; ponatinib; rigosertib; rociletinib; VS-5584)13. 
Twelve predicted drugs are being investigated in the MATCH  trial14, five in the My Pathway  trial15 and 12 in the 
COXEN  trial16. As expected, only a minority of 12.5% (9/72) of drug approaches are non-targeted therapies.
For ten DGIs reasonable combinational therapies could be identified to avoid therapy evasion. Further-
more, at the time of investigation we found six of the identified combinational therapy approaches in clinical 
trials with mostly solid tumors (buparlisib + MEK-inhibition; gedatolisib + MEK-inhibition; lapatinib + AKT-
inhibition; paclitaxel + PI3K-inhibition; palbociclib + PI3K/mTOR-inhibition; selumetinib + mTOR-inhibition; 
trametinib + mTOR-inhibition)13.
The majority of the identified genes (16/21) are currently subject of clinical trials as prognostic markers or in 
reference to therapeutic decision making for BLCA therapy. However, at the time of our investigation DNMT3A, 
FBXW7, HRAS, RAF1 and TOP1 are not yet found as genomic markers in BLCA related clinical trials and we 
are the first to report them as potential candidates for marker-driven therapy  testing13. With FGFR3 we identi-
fied the first and as yet only genomic marker with a dependent FDA-approved drug for locally advanced and 
metastatic  BLCA17 amongst our predictions.
Divergence in drug response prediction. Within a majority of samples, drug response predictions 
depended on multiple different mutations. In each individual sample a directed response prediction (sensitivity/
resistance) for one drug could depend on different genes and therefore divergence of the direction of prediction 
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was possible (in the following referred to as “gene-dependent divergence”). In total, 252 pairs of drug and sample 
contained any kind of divergence, referring to 158 individual samples with multiple divergent predictions. We 
note that in a majority of samples 55% (228/412) the drug response predictions did not show any divergence. 
The 252 gene-dependent divergences found across the samples can be categorized into 122 within CIViC predic-
tions, 97 within manual curation, and 33 resulting from differences between CIViC and manual curation pre-
dictions (2 in CIViC: resistance/manual curation: support; 31 in CIViC: support/manual curation: resistance). 
Thus, in all of these cases multiple genes had been mutated that had different impacts on the drug response. We 
identified divergent predictions exclusively resulting in reference to 8 drugs (docetaxel; sirolimus; cetuximab; 
bevacizumab; lapatinib; oxaliplatin; gemcitabine; trastuzumab). Between-source divergences corresponded to 
3 drugs (cetuximab; sirolimus; gemcitabine). In total, predictions in only 1.2% (5/412) of samples included 
between-source divergence (arising exclusively from the curation of different DGIs across the curation sources).
Molecular subtypes and drug response prediction. We investigated whether the 21 genes from the 
identified gene panel as well as the 89 drugs with DRS information show different prevalence in the previously 
described molecular subtypes of bladder cancer from the consensus work from Kamoun et al.18. Among the 
identified genes, logistic regression and ANOVA analysis detected 9 genes with significant mutation prevalence 
differences across subtypes (see suppl. Figs. S6, S7), based on a significance level of p value < 0.01 after multiple 
testing correction. Of 89 drugs with available DRS information, 83 drugs showed significant prediction dif-
ferences between molecular subtypes (see suppl. Fig. S8a,b), based on a Kruskal–Wallis rank sum test with a 
significance level of p value < 0.01 after multiple testing correction.
Figure 5.  Oncoprint shows weighted evidence across samples based on drug response score (DRS) and 
curation support. Interacting genes are listed behind each drug. The direction/evidence categories are composed 
as following: Conflicting evidence: resistance prediction + DRS positive; Mutation dependent evidence: gene-
dependent prediction + DRS positive/gene-dependent prediction + no DRS; Resistance evidence: resistance 
prediction + no DRS; Sensitivity evidence: sensitivity unspecific prediction + no DRS/sensitivity prediction + no 
DRS/no genomic + DRS positive; Sensitivity strong evidence: sensitivity unspecific prediction + DRS positive/
sensitivity prediction + DRS positive. “ct” and “nct” refer to cancer-type specific and non-cancer-type specific as 
defined above. (R Core Team (2019). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. https ://www.R-proje ct.org/)57.
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Potential application of the drug and gene panel. The drug and gene panel resulting from our work-
flow is a groundwork for a personalized therapy testing approach for BLCA. Investigating the predicted drugs, 
we see agents that have been clinically tested in BLCA, such as EGFR-inhibitors like cetuximab. Furthermore, 
Figure 6.  Our drug response prediction workflow discovers a panel of genes and related drugs/drug-
combinations for personalized therapy in bladder cancer. The figure illustrates the final selection of drug-gene 
interactions (including combination treatments). “Sensitivity” and “resistance” refer to predicted sensitivity 
and resistance when the associated gene contains a respective variant. “Sensitivity unspecific” refers to genes 
where sensitivity to a particular drug could not be assigned to a particular variant but multiple variants would 
lead to the prediction. In “variant dependent” predictions, different variants within one gene can cause a 
divergent direction of the response prediction (sensitivity/resistance). (R Core Team (2019). R: A language and 
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mTOR-inhibitors like sirolimus, agents affecting the RAF/MEK/ERK pathway such as selumetinib, or PARP-
inhibitors such as olaparib appear in our panel. With 10 identified drug candidates, PI3K-inhibitors form a 
major group of which only three (buparlisib; copanlisib; taselisib) are currently in clinical testing explicitly in 
BLCA.
Figure 7 illustrates a blueprint for the future application of our workflow. The gene and drug panel can serve as 
a cost-efficient yet comprehensive molecular diagnostics that is tailored to BLCA tumors. To illustrate an exam-
ple, in the case of a significant PI3K-mutation (found in 38.8% (160/412) of all samples; see suppl Fig. S3) our 
algorithm predicted variant-dependent sensitivity to 22 drugs and 6 drug combinations (see Fig. 6). Additionally, 
three unspecific gene-dependent predictions for sensitivities were found alongside two predicted resistances. Both 
resistances refer to EGFR-inhibitors; cetuximab and trastuzumab. Moreover, predictions from our algorithm can 
be weighted in reference to the level of supporting evidence (only genomic/genomic + DRS information avail-
able) (compare Fig. 3; suppl. Fig. S2). Subsequently, testing of the predicted drug response in patient derived 
tumor models can generate several implications for future clinical administration (see Fig. 7e). The efficacy of 
predicted sensitivities from drugs of the same group (e.g. the PI3K-inhibitors buparlisib and gedatolisib) can 
be assessed preclinically. Similarly, the observed resistance predictions can be utilized as negative controls in 
testing the aforementioned tumor model. Both in vitro and in vivo results would mandatorily be reported to the 
database, the algorithm was interrogating at the outset, to increase or decrease the power of the underlying DGIs.
Discussion
Poor and unforeseeable outcomes of standard therapies in BLCA raise the question, whether empiric “one size 
fits all” therapy and testing approaches can be justified in the setting of notably individual  tumors7. Indeed, 
the genomic and transcriptomic diversity in BLCA offers a plethora of known actionable  targets6. For other 
cancer types single genomic aberrations have proven to be relevant therapy targets, e.g. BRAF mutations in 
melanoma or HER2 mutations in breast  cancer19,20. In contrast to single marker-driven diagnostics and deci-
sions, molecular tumor boards in the US (Mayo  Clinic21; Weill  Cornell22) as well as in Europe (DKFZ/NCT23; 
ETH Zurich/SwissMTB24) started to comprehensively investigate individual molecular tumor landscapes. They 
examined clinical knowledge across oncological entities resulting in (off-label) drug suggestions for these often 
end-of-treatment-line patients, with notable  responses24. Despite known targetable mutations, except of recently 
approved FGFR-inhibitors17 further genomic marker-driven therapies have yet to prove efficacy in BLCA. There-
fore, BLCA investigations in comprehensive marker-based drug response predictions are highly warranted.
This study introduces an algorithm to facilitate a personalized and highly automated genome- and transcrip-
tome-dependent in silico drug response prediction in BLCA. Furthermore, it identifies and avoids pitfalls of 
database derived drug response predictions in personalized medicine. Our workflow identified 21 genes cor-
responding to 72 drugs and drug combinations as candidates for genomic marker-driven therapy in BLCA. The 
majority of the identified drugs (45/72) are currently the subject of research for targeted therapy in BLCA and 
other cancer types. Importantly, even without any a priori focus, our algorithm identified the single approved 
genomic marker for targeted therapy in bladder cancer,  FGFR313. This may reinforce that our workflow is a 
valid approach for the identification of potentially relevant DGIs. Since the method was similarly applied to all 
genes, we can highlight the discovery of DNMT3A, FBXW7, HRAS, RAF1 and TOP1 as potential candidates for 
mutation-dependent pharmacotherapy, not having been reported in clinical studies up to this  point13.
Alongside the identification of new potential targets, our WES-based approach could increase sensitivity 
towards existing targets. Prior analyses using panel-based sequencing methods identified up to 60% predefined 
targetable lesions in BLCA  patients25. Our WES-based approach identified one or more of such lesions in 95% 
of muscle-invasive BLCA in the TCGA cohort. Furthermore, transcriptomic data added another level of evi-
dence to our predictions. Additional evidence on the transcriptome level is an even stronger indicator that (1) 
the variant observed on the genomic level has an impact and (2) that the drug actually has the predicted effect. 
Therefore, our algorithm offers a robust strategy for the prediction of promising targets in most patients with 
muscle-invasive BLCA.
Within the group of identified targetable alterations, we found examples of altered genes playing notable 
parts in the pathogenesis of BLCA. DNA methylation regulation is crucially dependent on the DNMT3A gene 
product. Its mutations are described in many cancer  entities22. In BLCA, mutated DNMT3A is known to cause 
hypermethylation and thereby silence promoters of tumor suppressor  genes23. So far it is not reported as a 
genomic marker for a targeted therapy approach in BLCA. In the case of DNMT3A activating mutations, our 
algorithm acknowledged this pathogenetic mechanism and suggested use of the DNA methyltransferase inhibi-
tor decitabine.
The potential importance of combinational therapies in personalized drug discovery became obvious during 
manual curation. In case of a PIK3CA mutation, our algorithm suggested CDK4/CDK6-inhibitor palbociclib. 
CDK4/CDK6 is affected downstream in the line of the PI3K (= PIK3CA) pathway, mediated by AKT and Cyclin-
D. Due to according references with synergistic efficacy of a combined inhibition of PI3K and CDK4/CDK6, e.g. 
in breast cancer models, manual curation suggested PI3K-inhibition in combination with palbociclib in case of 
PIK3CA  mutation26.
Drug filtering and manual curation after the identification of DGIs using DGIdb.org uncovered several key 
findings. We have found that a majority of DGIs were dismissed due to both drug and gene related reasons. Drugs 
were dismissed due to an absence of evidence as cancer therapies; they were for example investigated in drug 
metabolism instead. We suggest that databases for disease-drug-gene relations, instead of drug-gene interactions 
only, would address this problem. Filtering thresholds caused some DGIs to be dismissed due to low cohort 
prevalence. These thresholds were chosen to create a drug and gene panel of manageable size. However, these 
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excluded DGIs could be of future interest. Ongoing research and the ever-increasing evidence base of expert 
curated databases such as CIViC will eventually overcome cohort prevalence barriers.
During manual curation many non-curated DGIs had to be dismissed due to missing evidence supporting 
the provided DGI. For instance, simple occurence of the drug or gene name in the list of references of a quoted 
article led to a non-curated DGI. Such DGIs were dismissed because said article might not have studied the effi-
cacy of this DGI. Automation and introduction of artificial intelligence may solve the problem of vague DGIs. In 
Figure 7.  Blueprint for future clinical applications. (a) Histologic samples are derived from the tumor mass 
and processed into (b) individual patient derived tumor models. (c) Tumor mass and tumor models undergo 
sequencing to confirm genomic comparability. (d) Sequencing results are analyzed with our algorithm for drug 
response predictions. Delivering weighted (level of support) and directed (sensitivity/resistance) predictions, the 
most promising sensitivities can be selected to be tested against predicted resistances, functioning as negative 
controls. (e) The derived proposals are tested in the patient derived models. (f) The drug with the best response 
is administered to the patient, while feedback about in vitro sensitivities and resistances is reported to the 
database. (g) Clinical response is also reported to databases (DGIdb; CIViC etc.), increasing or decreasing the 
power of the DGIs for the next query of the algorithm. (Procreate, Version X, https ://procr eate.art).
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2019 Kim et al. introduced the artificial intelligence based search engine for disease-gene-chemical relationships 
DigChem, which is able to avoid aforementioned text-mining errors. However, their study emphasized that the 
overlap with other DGI databases  (CTD27, IBM Watson for Drug  Discovery28 and  DrugBank29) is complemen-
tary, rather than displaying directly comparable  results30. Moreover, in the process of DGI filtering we found a 
large disparity between provided DGIs and the ratio of expert curated DGIs. Therefore, we conclude that manual 
curation has still to be considered mandatory to achieve evidence-based DGIs.
Although only in a minority of samples, we identified divergent drug response predictions due to the pres-
ence of multiple DGIs per sample and due to non-matching genome- and transcriptome-based predictions. A 
majority of divergences resulted from drugs with multiple-gene dependent response predictions within a given 
sample. In these cases model and clinical testing will facilitate judgment about the dominant DGI. Importantly, 
at the time of investigation a majority of samples were free of divergences in drug response prediction.
Both curations, manual and CIViC based, identified more sensitivities than resistances in DGIs. Although val-
idation is missing so far, we credit this fact to a known reporting bias for positive study results e.g.  sensitivities31. 
For the creation of comprehensive DGI databases a more liberal reporting of resistances will be essential. Siu 
et al. have addressed the need for liberal and barrier-free reporting of DGIs in creating a scheme for responsible 
sharing of cancer genome data for utilization in comprehensive  analysis32. Therefore, testing and reporting of drug 
resistance in DGIs as consequently as existing reporting of drug sensitivities, will be of paramount importance. 
Integration of proven and disproven drug-gene interactions into open source databases will be of utmost impor-
tance to improve drug response predictions. Prospectively, our workflow will include these growing databases 
and consequently predict promising drugs contemporaneously.
A subtype specific investigation of the prevalence of the referred genes identified significant differences for 9 
genes. While this might hint towards an explanation for a different clinical behaviour of the molecular subtypes 
to standard  therapies5, the low prevalence of the genes within the subtypes (see suppl. Figs. S6, S7) underlines 
the subtype heterogeneity. Subsequently, alongside supporting the predictive value of molecular subtypes for 
clinical decision making, our results underline the necessity for an even finer granularity of therapy selection 
criteria for a truly personalized therapy.
Biologically, advanced tumor stages are characterized by the consequences of multiple prior therapies and 
of progressed intratumor heterogeneity. Taking tumor evolution theories into account a plethora of potential 
therapy evasion mechanisms might have developed by that time and create limitations to personalized therapy 
so  far33. However, our algorithm can be adapted for testing in patient derived tumor models and thereby offers 
a tool to facilitate testing in multiple tumor stages and of multiple locations (e.g. metastases). The remarkable 
findings of Biswas et al.34, demonstrated mutational similarities between different evolutionary tumor branches. 
These findings might open the door to solutions how to address intratumor heterogeneity with targeted therapies. 
In our opinion, developing a dynamic understanding of oncogenesis and its underlying processes of therapy 
evasion development is compelling. It will allow for multi-time and multi-location evaluation of tumors and 
lead to accordingly individualized therapies.
We acknowledge that our approach is still hypothesis-generating and further validation is needed. Depend-
ing on databases which become extended by time, the results of our algorithm are fluent. We point out that in 
the future, querying our algorithm would deliver other results than by the time of our investigation. By evolving 
evidence our results can be supported, so that weak predictions turn into strong predictions and vice versa; novel 
predictions are possible caused by new results which are fed into the databases. At the same time, contradicting 
new evidence can enfeeble DGIs as well.
Hence, we want to underline the showcase character of this study. The fluent character of the algorithm is illus-
trated in Fig. 7d–g. Therefore, our algorithm can deliver an up-to-date base for mutation dependent personalized 
drug testing, rather than offering a more or less static truth. Ultimately, the in silico drug response predictions 
require further testing in patient derived models and clinical trials prior to implementation as personalized 
approaches in clinical practice. Importantly, clinical trials need to be designed in a genomic-marker aware fash-
ion. In 2019, preliminary data from the BISCAY trial compared the efficacy of the PD-L1 checkpoint inhibitor 
durvalumab in combination with targeted therapies in selected urothelial cancer patients. Despite achieving a 
superior overall response rate with the combination of durvalumab and the PARP inhibitor olaparib in case of 
an DNA-damage-repair gene alteration, compared to durvalumab monotherapy none of the study arms could 
reach the threshold for a positive study  result35. In 2017 Kiss et al. demonstrated that genomic variations and 
their impact as prognostic markers for therapy response, have to be carefully interpreted with consideration of 
transcriptional and gene-regulatory factors as well as of co-existing  mutations36. These findings highlight the 
importance of marker-driven trials. Basket-trials such as the My Pathways study (NCT02091141) or the NCI-
MATCH study (NCT02465060) offer access to individualized treatment with a diversity of targeted agents. Our 
algorithm represents a sophisticated tool that can be implemented in clinical trials and lay the foundation to 
precise cancer therapy based on a comprehensive understanding of molecular oncogenesis.
In conclusion, our algorithm for in silico drug response prediction in BLCA identified drugs with proven 
antitumor activity but importantly also new potentially druggable targets and novel drugs, which have not yet 
been tested in BLCA. Moreover, our drug prediction provided evidence for 95% of BLCA samples, highlight-
ing its applicability to the majority of bladder cancer patients. Integration of genomic and transcriptomic data 
acknowledged different regulatory processes in oncogenesis and increased the granularity of our predictions. 
Importantly, our algorithm yielded an efficient and affordable gene panel for drug response prediction based 
on a comprehensive approach. While we showcased the potential in this in-depth study of the bladder cancer 
patient cohort of TCGA, the workflow itself is applicable to any cancer type. Other available TCGA cohorts will 
provide a very valuable resource to perform the proposed semi-automated drug response prediction that could 
indicate future therapies for a genomic-driven personalized cancer therapy.
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Methods
The Cancer Genome Atlas bladder cancer cohort. We analyzed the genomic landscape of the 412 
bladder cancer patients of the TCGA-BLCA  cohort6. Based on the whole exome sequencing (WES) information, 
variants in the tumor genome have been identified and linked to their potentially targeting drugs. We prioritized 
variants and drugs according to their clinical relevance and prevalence in bladder cancer patients. The workflow 
is depicted in Fig. 1 and detailed in the following. The 412 patients in the TCGA-BLCA cohort present a well-
mixed population, e.g. in regard to gender, BLCA subtype, and tumor stage, which will likely reduce the effect of 
clinical features on the drug prediction results.
For each patient in the TCGA-BLCA cohort, the WES-based bam files for normal as well as tumor samples 
have been downloaded from the GDC data  portal37. Bam files had already been generated with the GDC data 
harmonization  workflow38. For patients with multiple tumor and/or normal samples, we selected the sample 
with the later plate number according to the GDC  guidelines39, and preferred fresh frozen over FFPE samples. 
Further, to ensure a sample selection as homogeneous as possible, we selected the blood derived normal whenever 
possible, as this was the normal control available for the majority of patients.
Variant calling from the TCGA cohort. To investigate the genomic landscape of the 412 bladder cancer 
patients, we performed somatic variant calling for the identification of single nucleotide variants (SNVs), as 
well as copy number calling to identify copy number variants (CNVs). The pipeline for WES analysis from the 
retrieved bam files to unannotated variant calls is based on the framework described in Singer et al.40, employing 
the Snakemake workflow  environment41.
SNVs. In brief, variants were called based on the GATK best practices  workflow42, with somatic variant call-
ing on the matched tumor and normal samples. To achieve high quality calls and reduce the number of false 
positives, we applied three different variant callers and only considered variants that were identified by at least 
two callers. The utilized variant callers were  MuTect43,  Strelka44, and  VarScan245, where the latter two not only 
perform single nucleotide variant calling, but also identify small insertions and deletions in the sample.
Variants were annotated using  SNPeff46 and  SNPsift47 and enriched with information on their presence in 
 ClinVar48,  COSMIC49, and  dbSNP50, as well as their overall mutation impact (e.g. missense variant or synonymous 
variant). We also performed a functional annotation to assess the potential of each variant to be damaging for 
the protein function.
CNVs. We used the CNV caller  Facets51 to call copy number variants on the matched tumor and normal sam-
ples for each patient. All CNVs were annotated to identify the affected genes.
In silico drug prediction and selection. Similarly as described in Singer et al.24, we queried  DGIdb7,52,53 
to identify the drug-gene interactions reported in a collection of 30 databases, of which several are expert-
curated (e.g.  MyCancerGenome54). The more databases support an interaction, the higher the scoring of the 
drug. Finally, based on drug-gene interactions identified in DGIdb we collected associated clinical trials at Clini-
calTrials.gov. Here, we distinguished between clinical trials in BLCA and those also including solid tumors (can-
cer type, “ct”), non-cancer type specific (“nct”) trials, and trials not related to cancer in general (“other”). Trials in 
the “nct” category focus on patients with other cancer types, thus for bladder cancer patients their corresponding 
drugs would potentially be regarded as off-label therapy.
Integrating clinical trial information provides a first prioritization of the drug-gene interactions (DGIs) 
resulting from the DGIdb query. The initial set of possible drugs was filtered to only contain drugs that have 
previously been tested in cancer-related clinical trials (categories “ct” and “nct”). Further, we prioritized drugs 
according to their frequency in the cohort, to obtain a set of drugs that is likely to contain at least one possible 
match for each BLCA patient.
Variant prioritization and selection. The set of identified variants (both SNVs and CNVs) was filtered to 
prioritize variants that are likely to be of clinical relevance, i.e. that (1) are likely to have an impact on the protein 
function and (2) that are associated with genes with DGIs listed in DGIdb. An overview of the filtering process 
is illustrated in Fig. 1. SNVs were filtered to only include those that have a high impact (higher than 20, based on 
the SNPeff impact list, see suppl. Table S1) and that are predicted to be damaging. The CNVs were filtered to only 
include those with deep deletions (copy number = 0) or high amplifications (copy number > 4).
Further, we only included variants that affect genes with a reported drug-gene interaction (based on the 
DGIdb query). Furthermore, we prioritized variants that occur more frequently across the TCGA-BLCA cohort, 
to obtain a final selection that is not only likely to be of clinical relevance, but also likely to have at least one 
targetable variant present in BLCA patients.
The minimum set cover analysis was performed to identify the fraction of the cohort that was covered by the 
selected set of priority genes (and drugs). It was based on in-house scripts and performed a greedy selection of 
the best possible set.
Integration of CIVIC. The information provided by DGIdb is very comprehensive and thus a valuable 
resource to provide a basic set of DGIs as a starting point. However, it has several limitations that impede its 
direct use for clinically relevant in silico drug prediction. First of all, it is undirected and only lists DGIs without 
indicating the nature of the DGI, i.e. whether a mutation in the respective gene confers sensitivity or resistance. 
Second, it only reports interactions between genes and drugs and does not consider the individual variants pre-
12
Vol:.(1234567890)
Scientific Reports |         (2021) 11:5849  | https://doi.org/10.1038/s41598-021-85151-3
www.nature.com/scientificreports/
sent in a patient’s tumor. And finally, it contains not only expert-curated databases such as MyCancerGenome.
org, but also comprehensive compound collections. As a consequence, we enriched the DGIdb based informa-
tion with variant specific expert curated information from the CIViC  database8. Here, individual aberrations 
that affect a specific gene are evaluated for their potential to confer sensitivity or resistance to a drug, and each 
evaluation (called evidence item) is rated with an evidence level to show the quality of the underlying informa-
tion. For instance, preclinical studies are rated lower than information gained from multi-center clinical trials. 
Our CIViC based assessment of each DGI is accordingly applied on the variant level, such that in case different 
TCGA samples showed different variants of the same gene, a DGI can have divergent readouts, i.e. sensitivity or 
resistance. Note that it is possible that a variant-drug interaction type is not clearly identifiable from the informa-
tion currently available in CIViC, e.g. in some studies a variant seemed to confer sensitivity while in other studies 
this was not a significant finding. In these “CONFLICT” cases we employ a majority vote that counts how many 
evidence items support sensitivity and resistance, respectively, and take the interaction type supported by the 
majority of evidence items. Note that before the majority vote is applied, we prioritize the evidence items accord-
ing to their relevance, e.g. evidence items on bladder cancer would be prioritized over those with information 
from other cancer types. Further, CIViC contains evidence items that are not explicitly in favor of either sensi-
tivity or resistance. Accordingly, the corresponding DGI is labeled as “UNKNOWN” to indicate that the DGI 
was found in CIViC, but that the available information is not sufficient to clearly predict response or resistance.
Manual curation of drug–gene interaction. References of DGIs obtained from the DGIdb query with 
no annotation in the curated CIViC database were selected for manual curation. Clinical studies as well as 
experimental studies were included. First, categories for response were separated into “SENSITIVITY”, “RESIST-
ANCE” and “UNKNOWN”. The category “UNKNOWN” thereby summarized all references with missing evi-
dence of single agent activity, effectiveness or missing reference to the drug or gene itself. An annotation category 
was added to document restrictions such as: quality of data, conflicting evidence, variant dependent response, 
co-variant dependent response, gene expression dependent response, reasonable combinational therapy to avoid 
therapy evasion and clinically relevant information about the drug. Second, the full text articles referenced by 
DGIdb were screened for the gene and the active substance. If the active substance name was not found, generic 
names, brand names and accession numbers were searched for.
If gene and drug were found, data was screened to support single agent activity of the drug in clear reference 
to an explicit mutation and/or wild type. In clinical studies response “SENSITIVITY” was defined as improve-
ment of response rate, progression of free survival or overall survival under administration of the drug, in case 
of mutated gene compared to wild type. Response “RESISTANCE” was here defined as decreased response rate, 
inferior progression free survival or overall survival under administration of the drug, in case of a mutated gene 
compared to wild type. In experimental studies, response “SENSITIVITY” was defined as deteriorated growth or 
decreased survival of the tumor model under administration of the drug, in case of mutated gene compared to 
wild type. Response “RESISTANCE” was defined as accelerated growth or increased survival of the tumor model 
under administration of the drug, in case of mutated gene compared to wild type. Response “UNKNOWN” was 
defined as no significant difference of clinical outcome or tumor model reaction when comparing mutant to wild 
type. References with missing evidence of single agent activity, effectiveness of the administered drug or missing 
reference to the drug or gene itself, were classified as response “UNKNOWN” as well.
Integration of DRS. We used the CellMiner tool to mine for drug response correlating to expression data 
of the NCI-60 cell  lines55. As previously published, corresponding genes were used to generate patient specific 
drug response scores (DRS) using correlation coefficients as weighting  factors56. Thereby, DRS represent a state-
ment on a potential drug response based on the level of expression of a certain gene product. Hence, a positive 
DRS is a prediction of a drug sensitivity, as the underlying investigations correlated tumor model response to a 
certain level of gene product expression. However, a negative DRS does not predict a therapy resistance, but a 
non-response to the drug.
Molecular subtype analysis. To investigate potential differences in the distribution of the identified tar-
getable genes across the molecular  subtypes18, we performed logistic regression coupled to an ANOVA inde-
pendently for each gene. We excluded samples not covered by the consensus definition (n = 6) as well as those 
assigned as “NE-like” (due to the small size of this group, n = 6). The null hypothesis for this test is that the 
molecular subtype has no influence on the mutation prevalence.
Using the Kruskal–Wallis rank sum test, we compared the DRS scores across the molecular subtypes inde-
pendently for each available drug. For this analysis, we only considered the 405 patients having DRS information 
available and again excluded patients without a subtype definition and those belonging to the “NE-like” subtype, 
due to low sample sizes.
In both cases, multiple testing correction was applied using the Benjamini–Hochberg method.
Data availability
The data that support the findings of this study are available from the corresponding author upon request.
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